Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials
- 3 October 2016
- journal article
- conference paper
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 33 (10), 895-906
- https://doi.org/10.1002/da.22500
Abstract
Kappa‐opioid receptor (KOR) antagonists are currently being considered for the treatment of a variety of neuropsychiatric conditions, including depressive, anxiety, and substance abuse disorders. A general ability to mitigate the effects of stress, which can trigger or exacerbate these conditions, may explain their putative efficacy across such a broad array of conditions. The discovery of their potentially therapeutic effects evolved from preclinical research designed to characterize the molecular mechanisms by which experience causes neuroadaptations in the nucleus accumbens (NAc), a key element of brain reward circuitry. This research established that exposure to drugs of abuse or stress increases the activity of the transcription factor CREB (cAMP response element binding protein) in the NAc, which leads to elevated expression of the opioid peptide dynorphin that in turn causes core signs of depressive‐ and anxiety‐related disorders. Disruption of KORs—the endogenous receptors for dynorphin—produces antidepressant‐ and anxiolytic‐like actions in screening procedures that identify standard drugs of these classes, and reduces stress effects in tests used to study addiction and stress‐related disorders. Although interest in this target is high, prototypical KOR antagonists have extraordinarily persistent pharmacodynamic effects that complicate clinical trials. The development of shorter acting KOR antagonists together with more rapid designs for clinical trials may soon provide insight on whether these drugs are efficacious as would be predicted by preclinical work. If successful, KOR antagonists would represent a unique example in psychiatry where the therapeutic mechanism of a drug class is understood before it is shown to be efficacious in humans.Keywords
This publication has 108 references indexed in Scilit:
- Repeated Exposure to the κ-Opioid Receptor Agonist Salvinorin A Modulates Extracellular Signal-Regulated Kinase and Reward SensitivityBiological Psychiatry, 2011
- Kappa Opioid Receptor Signaling in the Basolateral Amygdala Regulates Conditioned Fear and Anxiety in RatsBiological Psychiatry, 2011
- Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbensPsychopharmacology, 2010
- Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley ratsPsychopharmacology, 2010
- The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abusePsychopharmacology, 2010
- kappa-Opioid receptor signaling and brain reward functionBrain Research Reviews, 2009
- Dynorphin, stress, and depressionBrain Research, 2009
- The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviorsBrain Research, 2009
- The Kappa-Opioid Agonist U69,593 Blocks Cocaine-Induced Enhancement of Brain Stimulation RewardBiological Psychiatry, 2008
- Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodynEuropean Journal of Pharmacology, 2007